Olomorasib
Term · Oncology and biomedicine · MLC-T-ONC-015609
An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, olomorasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.
| Identifier | MLC-T-ONC-015609 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | KRAS G12C inhibitor LY3537982 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015609",
"term": "Olomorasib",
"field": "Oncology and biomedicine",
"definition": "An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, olomorasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.",
"synonyms": [
"KRAS G12C inhibitor LY3537982"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/olomorasib/"
}
Record 12,150 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.